The Government of Nova Scotia is expanding the use of biosimilar medications in Nova Scotia Pharmacare programs. Starting 3 February 2023, some original biologic medications won’t be covered by Pharmacare if a biosimilar version is approved and available, unless an exemption is granted.
To start switching patients to biosimilars, prescribers need to:
Pharmacare can provide you with a list of your patients who may need to switch to a biosimilar medication. To receive this list, fill out the Patient List Request form and email it to email@example.com or fax it to 902-428-3400.
A clinical support staff member is available to help you organize, reduce administrative burden and provide education where needed. To contact the clinical support staff, email firstname.lastname@example.org.
The following changes to biosimilar coverage apply:
Prescribers can apply for an exemption if a patient can’t switch to a biosimilar for clinical reasons. Fill out an Exception Status Drug Request for patients who can’t switch and provide detailed clinical rationale for the exception.
If this exemption is not approved or the patient doesn’t qualify for an exemption, their coverage for the original biologic medication will end.
|Drug||Originator (switch from)||Biosimilar (switch to)||Indications (if applicable)|
adult ulcerative colitis
polyarticular juvenile Idiopathic arthritis
polyarticular juvenile idiopathic arthritis
*NovoRapid vials will be covered until a biosimilar in a vial format is approved.
The policy will apply to other medications on the Nova Scotia Formulary as new biosimilar medications are approved.
Department of Health and Wellness Clinical Support Staff